DC Longitudinal Study on Aging and Specimen Bank
(DC LSOA)
1 other identifier
observational
1,000
1 country
1
Brief Summary
The Georgetown University Memory Disorders Program, part of the Department of Neurology, is conducting pilot studies of the feasibility of various diagnostic tests for Alzheimer's disease, mild cognitive impairment and other neurodegenerative diseases. Further, this study is assessing longitudinal changes in biological, lifestyle, and cognitive assessment collection. The primary goal of this study is to examine the feasibility of biochemical assays, genetic testing, and cognitive and lifestyle assessments in the ante-mortem diagnosis of Alzheimer's disease, mild cognitive impairment and other neurodegenerative diseases. This research involves genetic and cognitive status testing but the findings will not be shared with research subjects. This will be accomplished ex vivo using blood, and/or cerebrospinal fluid (CSF) specimens from patients with a diagnosis of probable Alzheimer's disease, mild cognitive impairment, or other neurodegenerative diseases and from normal controls.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2007
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2007
CompletedFirst Submitted
Initial submission to the registry
October 9, 2018
CompletedFirst Posted
Study publicly available on registry
October 11, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2027
October 24, 2019
October 1, 2019
20 years
October 9, 2018
October 23, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
CDR
Clinical Dementia Rating
9 years
Study Arms (2)
Normal Cognition
No diagnosis of a cognitive disorder
Cognitive Disorder
Diagnosed with a cognitive disorder such as :Mild Cognitive Impairment, Alzheimer's disease, Frontotemporal Dementia, Lewy Body Dementia, Vascular Dementia, or other neurodegenerative condition.
Eligibility Criteria
All genders, races, and ethnicities eligible. Normal controls and those diagnosed with a neurodegenerative disorder eligible.
You may qualify if:
- Age 45 and older.
- Subjects within the age range of 45-50 years old must have a first degree relative with a neurodegenerative disease.
You may not qualify if:
- Individuals under 45 years of age
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Georgetown University Memory Disorders Program
Washington D.C., District of Columbia, 20057, United States
Related Links
Biospecimen
Collection of Blood Collection of Cerebrospinal Fluid (CSF) (Optional)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director
Study Record Dates
First Submitted
October 9, 2018
First Posted
October 11, 2018
Study Start
January 1, 2007
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
January 1, 2027
Last Updated
October 24, 2019
Record last verified: 2019-10
Data Sharing
- IPD Sharing
- Will not share